Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 6025358, 8 pages
https://doi.org/10.1155/2017/6025358
Research Article

Identification of NURR1 (Exon 4) and FOXA1 (Exon 3) Haplotypes Associated with mRNA Expression Levels in Peripheral Blood Lymphocytes of Parkinson’s Patients in Small Indian Population

Department of Biotechnology, Sathyabama University, Chennai 600119, India

Correspondence should be addressed to Jayshree Nellore; moc.oohay@erollen_eers

Received 20 October 2016; Revised 29 December 2016; Accepted 10 January 2017; Published 31 January 2017

Academic Editor: Cristine Alves da Costa

Copyright © 2017 Jayakrishna Tippabathani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. John, “Multi-disciplinary care for Parkinson’s must, say docs. Lifestyle Health and Wellbeing,” Deccan Chronicle, http://www.deccanchronicle.com.
  2. C. W. Olanow, M. B. Stern, and K. Sethi, “The scientific and clinical basis for the treatment of Parkinson disease (2009),” Neurology, vol. 72, no. 21, S4, pp. S1–S136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Shi, B. R. Huber, and J. Zhang, “Biomarkers for cognitive impairment in parkinson disease,” Brain Pathology, vol. 20, no. 3, pp. 660–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Buttarelli, Francesca, A. Fanciulli, C. Pellicano, and F. E. Pontieri, “The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders,” Current Neuropharmacology, vol. 9, no. 2, pp. 278–288, 2011. View at Google Scholar
  5. F. Blandini, A. Mangiagalli, M. Cosentino et al., “Peripheral markers of apoptosis in parkinson's disease: the effect of dopaminergic drugs,” Annals of the New York Academy of Sciences, vol. 1010, no. 1, pp. 675–678, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. R. Scherzer, A. C. Eklund, L. J. Morse et al., “Molecular markers of early Parkinson's disease based on gene expression in blood,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 955–960, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Doucet-Beaupré and M. Lévesque, “The role of developmental transcription factors in adult midbrain dopaminergic neurons,” OA Neurosciences, vol. 1, no. 1, article no. 3, 2013. View at Publisher · View at Google Scholar
  8. K. N. Alavian, C. Scholz, and H. H. Simon, “Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death,” Movement Disorders, vol. 23, no. 3, pp. 319–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Jankovic, S. Chen, and W. D. Le, “The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease,” Progress in Neurobiology, vol. 77, no. 1-2, pp. 128–138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Torii, T. Kawarai, S. Nakamura, and H. Kawakami, “Organization of the human orphan nuclear receptor Nurr1 gene,” Gene, vol. 230, no. 2, pp. 225–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-S. Kim, C.-H. Kim, D.-Y. Hwang et al., “Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner,” Journal of Neurochemistry, vol. 85, no. 3, pp. 622–634, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Hermanson, B. Joseph, D. Castro et al., “Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells,” Experimental Cell Research, vol. 288, no. 2, pp. 324–334, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Smits, T. Ponnio, O. M. Conneely, J. P. H. Burbach, and M. P. Smidt, “Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons,” European Journal of Neuroscience, vol. 18, no. 7, pp. 1731–1738, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. W.-D. Le, P. Xu, J. Jankovic et al., “Mutations in NR4A2 associated with familial Parkinson disease,” Nature Genetics, vol. 33, no. 1, pp. 85–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. S. R. W. Stott, E. Metzakopian, W. Lin, K. H. Kaestner, R. Hen, and S.-L. Ang, “Foxa1 and Foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages,” The Journal of Neuroscience, vol. 33, no. 18, pp. 8022–8034, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. T. Sutherland, N. A. Matigian, A. M. Chalk et al., “A cross-study transcriptional analysis of Parkinson's disease,” PLoS ONE, vol. 4, no. 3, Article ID e4955, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Coldspring-Harbour Laboratory Press, London, UK, 3rd edition, 2001.
  19. M. Orita, H. Iwahana, H. Kanazawa, K. Hayashi, and T. Sekiya, “Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 8, pp. 2766–2770, 1989. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Pankratz, W. C. Nichols, S. K. Uniacke et al., “Significant linkage of Parkinson disease to chromosome 2q36-37,” American Journal of Human Genetics, vol. 72, no. 4, pp. 1053–1057, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. G. F. Wooten, L. J. Currie, V. E. Bovbjerg, J. K. Lee, and J. Patrie, “Are men at greater risk for Parkinson's disease than women?” Journal of Neurology, Neurosurgery & Psychiatry, vol. 75, no. 4, pp. 637–639, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Bannon, B. Pruetz, A. B. Manning-Bog et al., “Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6382–6385, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Pan, W. Xie, J. Jankovic, and W. Le, “Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease,” Neurology, vol. 62, no. 7, article A108, 2004. View at Google Scholar
  24. W. Le, T. Pan, M. Huang et al., “Decreased NURR1 gene expression in patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 273, no. 1-2, pp. 29–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Liu, L. Wei, Q. Tao et al., “Decreased NURR1 and PITX3 gene expression in Chinese patients with Parkinson's disease,” European Journal of Neurology, vol. 19, no. 6, pp. 870–875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Pérez-Sieira, M. López, R. Nogueiras, and S. Tovar, “Regulation of NR4A by nutritional status, gender, postnatal development and hormonal deficiency,” Scientific Reports, vol. 4, article no. 4264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Matsuki, M. To, Y. Kondo et al., “Associations between brain-derived neurotrophic factor and estradiol in women's saliva,” Neuroendocrinology Letters, vol. 35, no. 3, pp. 236–241, 2014. View at Google Scholar · View at Scopus
  28. M. A. Hauser, Y.-J. Li, H. Xu et al., “Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism,” Archives of Neurology, vol. 62, no. 6, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Zhang, M. James, F. A. Middleton, and R. L. Davis, “Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms,” American Journal of Medical Genetics—Neuropsychiatric Genetics, vol. 137, no. 1, pp. 5–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. L. B. Moran, D. C. Duke, M. Deprez, D. T. Dexter, R. K. B. Pearce, and M. B. Graeber, “Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease,” Neurogenetics, vol. 7, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. T. G. Lesnick, S. Papapetropoulos, D. C. Mash et al., “A genomic pathway approach to a complex disease: axon guidance and Parkinson disease,” PLoS Genetics, vol. 3, no. 6, article e98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Domanskyi, H. Alter, M. A. Vogt, P. Gass, and I. A. Vinnikov, “Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance,” Frontiers in Cellular Neuroscience, vol. 8, article no. 275, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. E.-K. Tan, H. Chung, Y. Zhao et al., “Genetic analysis of Nurr1 haplotypes in Parkinson's disease,” Neuroscience Letters, vol. 347, no. 3, pp. 139–142, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Grimes, F. Han, M. Panisset et al., “Translated mutation in the Nurr1 gene as a cause for Parkinson's disease,” Movement Disorders, vol. 21, no. 7, pp. 906–909, 2006. View at Publisher · View at Google Scholar · View at Scopus